Title:
TISSUE-SPECIFIC PROMOTER AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/071905
Kind Code:
A1
Abstract:
Provided are a tissue-specific promoter and use thereof. The tissue-specific promoter has a nucleic acid sequence comprising more than 80% of the sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. The tissue-specific promoter can promote the specific expression of a coding gene in endothelial cells (ECs) or megakaryocyte-platelet cells and can be applied to gene therapy in which a gene is required to be specifically expressed in ECs or megakaryocyte-platelet cells, ensuring a therapeutic effect, reducing a risk of immune rejection and saving a therapeutic cost.
Inventors:
CHANG LUNG-JI (CN)
GONG JIE (CN)
GONG JIE (CN)
Application Number:
PCT/CN2022/126404
Publication Date:
May 04, 2023
Filing Date:
October 20, 2022
Export Citation:
Assignee:
BEIJING MEIKANG GENO IMMUNE BIOTECHNOLOGY CO LTD (CN)
International Classes:
A61K48/00; C12N15/113; A61P7/04; C12N5/10; C12N7/01; C12N15/12; C12N15/867
Foreign References:
| CN114032239A | 2022-02-11 | |||
| US20180044634A1 | 2018-02-15 | |||
| CN113248594A | 2021-08-13 | |||
| CN112575034A | 2021-03-30 |
Other References:
P A RADCLIFFE ET AL.: "Analysis of factor VIII mediated suppression of lentiviral vector titres", GENE THERAPY, vol. 15, no. 4, 29 November 2007 (2007-11-29), XP037778730, ISSN: 0969-7128, DOI: 10.1038/sj.gt.3303080
Attorney, Agent or Firm:
BEYOND ATTORNEYS AT LAW (CN)
Download PDF: